MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fonc.2026.1809354

Медицинская библиотека · Frontiers in oncology · 2026

A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers (KITE-439 trial).

Kirtane Kedar, Niu Jiaxin, Blumenschein George, Massarelli Erminia, Hanna Glenn J, Lee Sylvia, Bishop Michael R, Konecny Gottfried E, Mao Daqin, Zheng Yan, Rodriguez Katherine, Kim Jenny J, Williams Chad, Schweitzer Colleen, Adhikary Sabina, Jung A Scott, Klebanoff Christopher A

СтатьяПеревод пока не подготовлен

Аннотация

Patients with relapsed/refractory (r/r) HPV-associated epithelial cancers have a poor prognosis. Engineered T cells expressing a T cell receptor (TCR) specific for HPV16 E7 can induce tumor regression. We conducted a Phase 1 trial of KITE-439, an investigational autologous T-cell product expressing TCR specific for HPV16 E7 in patients with r/r HPV16+ epithelial cancers. CD4+ and CD8+ T cells selected from leukapheresed peripheral blood mononuclear cells were stimulated with anti-CD3/anti-CD28 antibodies followed by retroviral transduction and expansion in the presence of interleukin-7/15 and an AKT inhibitor. Patients received lymphodepleting chemotherapy (cyclophosphamide 30 mg/kg/day for 2 days and fludarabine 25 mg/m2/day for 5 days) followed by a single infusion of KITE-439 with daily IL-2 (2.5×105 IU/kg, up to 7 doses). The primary objectives were safety, tolerability, and efficacy; the primary endpoint was dose-limiting toxicities (DLTs). Eight HLA-A*02:01+ patients received KITE-439 (1×106-1×108 cells/kg). No DLTs occurred during the trial. In all patients, KITE-439 cells were detected in peripheral blood within 7 days post-infusion. Three patients experienced Grade 1-2 cytokine release syndrome related to KITE-439 (resolved within 1-5 days) and 4 had KITE-439-related Grade 1-2 neurologic events (resolved within a day). One patient achieved a partial response (from Day 35 to Month 3) and 7 had a best response of stable disease. These results suggest that KITE-439 has an acceptable safety profile for the treatment of patients with HPV-associated epithelial cancers. Further studies are needed to determine optimal manufacturing conditions and T-cell characteristics required for enhanced antitumor activity.

Для цитирования: Kirtane Kedar, Niu Jiaxin, Blumenschein George, Massarelli Erminia, Hanna Glenn J, Lee Sylvia, Bishop Michael R, Konecny Gottfried E, Mao Daqin, Zheng Yan, Rodriguez Katherine, Kim Jenny J, Williams Chad, Schweitzer Colleen, Adhikary Sabina, Jung A Scott, Klebanoff Christopher A. A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers (KITE-439 trial).. Frontiers in oncology. 2026. DOI: 10.3389/fonc.2026.1809354.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.